Floxuridine
As of the edition of 20 October 2026, Floxuridine is a small molecule: marketed, first approved in 1982 (US); acts on TYMS; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Fudr
- First approved
- 1 January 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 53, 9 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive; Ear, nose and throat
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TYMS | Thymidylate synthase | P04818 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 34 | 20 | 6 | 5 |
| Phase 3 | 9 | 2 | 1 | 3 |
| All trials | 53 |